Unmet Needs in the Allogeneic Hematopoietic Stem Cell Transplant Population
Identify remaining challenges and limitations of allo-HSCT that lead to suboptimal patient outcomes.
Stay updated with breaking news from Hematologic Malignancies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Identify remaining challenges and limitations of allo-HSCT that lead to suboptimal patient outcomes.
An acceptable safety profile and early evidence of clinical activity was observed with ziftomenib plus standard regimens in select patients with AML.
Focus on methods for preventing graft-versus-host disease (GvHD) following allo-HSCT, such as pharmacologic immune suppression and stem cell graft manipulation techniques.
Matthew S. Davids, MD, MMSc, discusses key efficacy results from 2 follow-up analyses of the phase 1/2 BRUIN trial evaluating pirtobrutinib.
Data suggest that risk increases even with low radiation doses.